Momenta Pharmaceuticals Aktie
WKN: A0B5Q8 / ISIN: US60877T1007
13.02.2018 07:36:45
|
Sandoz Announces FDA Approval Of Glatopa - Quick Facts
(RTTNews) - Sandoz, a Novartis division, announced the US FDA approval and launch of Glatopa (glatiramer acetate injection) 40 mg/mL. The product is FDA-approved as a fully-substitutable, AP-rated generic version of Copaxone (glatiramer acetate injection) 40 mg/mL three times-a-week therapy for relapsing forms of multiple sclerosis.
Glatopa was developed under a collaboration agreement between Momenta Pharmaceuticals, Inc. and Sandoz.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Momenta Pharmaceuticals Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Momenta Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Novartis AG (Spons. ADRS) | 102,00 | -0,97% |
|